# A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

> **NCT00240448** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1109 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** telmisartan 80 mg/hydrochlorothiazide 25 mg
- **DRUG:** valsartan 160 mg/hydrochlorothiazide 25 mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00240448
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-06
- **Final completion:** —
- **Target enrollment:** 1109 (ACTUAL)
- **Last updated:** 2013-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240448, "A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00240448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*